

Personalized Healthcare System for Diabetes Patients Using Machine Learning Techniques

R. K. Jeyauthmigha¹, Dr. C. Sowmya Dhanalakshmi²

¹Department of Computer Science and Design, SNS College of Technology, Coimbatore 641035, Tamilnadu, India

²Department of Mechanical Engineering, SNS College of Technology, Coimbatore 641035, Tamilnadu, India

Abstract: Diabetes mellitus is one of the most common dreadful diseases, demand uninterrupted observation, proactive risk prediction, and individualized treatment strategies. Traditional healthcare methods often fail to account for the patient Characteristics, leading to inefficient management and delayed detection of complications. Recent advances in Conventional in machine learning (ML) have enabled the development of smart healthcare systems that can analyze biomedical, behavioral, and lifestyle data to deliver accurate predictions and tailored recommendations. This survey reviews advanced ML techniques utilized in personalized diabetes care, including supervised learning for risk prediction, unsupervised clustering for phenotype discovery, deep learning for continuous glucose monitoring (CGM) forecasting, and reinforcement learning for personalized insulin and lifestyle recommendations. It consolidates findings from studies focusing on diagnosis, disease progression modeling, complication detection, wearable-based monitoring, and treatment refinement. Various ML models, such as Support Vector Machines, Random Forests, Gradient Boosting, LSTM networks, Temporal Convolutional Networks, and Autoencoders, have showcased improved accuracy in predicting glycemic excursions, identifying critical groups, and ease individualized care. Data Aggregation from electronic health records (EHRs), Internet of Things (IoT) devices, and mHealth applications enhances continuous monitoring and proactive care. However, ongoing difficulties concerning understandability, data integrity, interoperability, information privacy, and comprehensive care. In conclusion, this study emphasize that ML-driven personalized healthcare systems have remarkable ability to transform blood glucose management. Future research should focus on developing explainable AI, structured datasets, privacy-preserving federated learning, and aid Human-AI synergy.

Keywords: Personalized healthcare, wearable sensors, risk prediction, phenotype clustering, reinforcement learning, explainable AI, federated learning.

1. Introduction

Diabetes mellitus is a booming global health issue characterized by chronic high blood glucose resulting from insulin deficiency, insulin resistance, or both. The commonness of diabetes has increased at an excessive rate, placing severe tension on healthcare systems worldwide due to its association with severe microvascular and macrovascular complications, including retinopathy, nephropathy, neuropathy, and cardiovascular diseases. Effective diabetes management therefore requires constant surveillance, emergent threat detection, and early intervention.

Traditional diabetes care primarily depends on periodic medical visits and clinical guidelines. Such methods frequently fail to capture individual variability in physiology, lifestyle, genetics, and disease progression, leading to poorly managed blood sugar, delayed complication diagnosis, and poor treatment. The increasing accessibility of healthcare data has open new horizons to eliminate these limitations.

Recent advances in machine learning (ML) have enabled the growth of personalized, data-centric diabetes management systems. ML techniques can study heterogeneous data sources such as electronic health records, continuous glucose monitoring data, wearable tracking, laboratory examinations, and lifestyle information to support early diagnosis, Blood Glucose Level Prediction, patient grouping, and therapeutic optimization. These potentiality position ML as a primary catalyst of precision healthcare in diabetes care.

Despite advancement, several problems remain, including Data consolidation, shallow personalization, reduced model

transparency, and insufficient broad-based validation across varied populations. In addition, most existing studies focus on individual tasks rather than all-inclusive, end-to-end personalized management frameworks. Inspired by these gaps, this study thoroughly examines machine learning approaches used in tailored diabetes care, assesses their advantages and disadvantages, and pinpoints unresolved research issues. The objective is to show future paths for creating ML-based solutions that are clinically deployable, scalable, and interpretable for better diabetes care.




Figure 1: An integrated, customized healthcare system for managing diabetes

Volume 15 Issue 9, September 2026

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net

2. Review of Literature

An intelligent system that integrated Random Forest and SVM classifiers with heuristic optimization for feature selection was proposed by Faris et al. [1]. Their technique demonstrated that hybrid models can enhance classification results with a prediction accuracy of about 92%. However, the study's use of a small dataset and lack of validation on a variety of demographics were its limitations.

In a systematic study of machine learning models for diabetes risk prediction, Han et al. [2] found that ensemble methods (Random Forest, Gradient Boosting) consistently perform better than single classifiers. To achieve reliable results, they stressed the importance of feature engineering, appropriate dataset preprocessing, and imbalanced class handling.

Naïve Bayes, Decision Tree, and SVM classifiers were compared for diabetes prediction by Sisodia and Sisodia [3]. According to their research, SVM fared better than other algorithms in managing high-dimensional feature spaces and attaining superior generalization. Despite this, clinical adoption was hampered by SVM models' poor interpretability.

Rahman and Rashid [4] compared boosting techniques like XGBoost and LightGBM with traditional algorithms. They discovered that in large-scale datasets, boosting methods offer better accuracy, better management of missing data, and increased robustness to noise. The study emphasized the significance of cross-validation techniques and hyperparameter adjustment in obtaining accurate predictions.

A thorough analysis of deep learning methods used for blood glucose prediction was carried out by Li et al. [5]. Using continuous glucose monitoring (CGM) data, the study methodically examined several neural network designs, including recurrent and convolutional models. Their results demonstrated that when it comes to short-term glucose predictions, deep learning models perform noticeably better than conventional statistical and machine learning techniques. The scientists did, however, also highlight issues that impede clinical implementation, such as a lack of defined evaluation measures, restricted dataset diversity, and decreased model interpretability.

A thorough analysis of deep learning methods used for blood glucose prediction was carried out by Li et al. [5]. Using continuous glucose monitoring (CGM) data, the study methodically examined several neural network designs, including recurrent and convolutional models. Their results demonstrated that when it comes to short-term glucose predictions, deep learning models perform noticeably better than conventional statistical and machine learning techniques. The scientists did, however, also highlight issues that impede clinical implementation, such as a lack of defined evaluation measures, restricted dataset diversity, and decreased model interpretability.

The use of reinforcement learning to optimize individualized insulin therapy was investigated by Peng et al. [7]. By modeling insulin dosage as a sequential decision-making problem, their method enables the system to interact with

patient data to learn the best treatment approaches. When compared to rule-based insulin delivery techniques, the results showed better glycemic control. The study recognized difficulties pertaining to patient safety, computational complexity, and the need for substantial training data prior to implementation in clinical settings, notwithstanding its potential.

To find unique subgroups of adult-onset diabetes, Ahlqvist et al. [8] developed a data-driven clustering framework. The study identified variation within diabetic populations that is not captured by conventional classification systems by examining clinical and biochemical factors. Precision medicine may be affected by these new subgroups' differences in disease progression and complication risk. However, the authors emphasized the necessity of long-term research to confirm these clusters' stability over time.

In order to find biologically different patient subgroups pertinent to diabetic therapy, Udler [9] looked into genetic clustering in type 2 diabetes. The study showed that genetic stratification can enhance long-term clinical outcomes in diabetes care by supporting individualized treatment planning and early identification of patients at higher risk for problems.

By using cluster-based classification for diabetic patients, Dennis et al. [10] demonstrated that grouping patients based on their clinical and metabolic characteristics might optimize healthcare decisions. Their results supported the use of precision medicine in the treatment of diabetes by highlighting advancements in therapeutic targeting and the avoidance of complications.

The UVA/Padova Type 1 Diabetes Simulator was created by Man et al. [11] as a virtual platform for studying insulin therapy approaches with a focus on healthcare. This simulator has been crucial in lowering patient risk, promoting innovation in clinical diabetes care, and safely assessing diabetes treatment algorithms.

A machine learning-based insulin bolus adviser was proposed by Xie et al. [12] to assist individualized diabetic self-management. By tailoring recommendations to each patient's reaction, the system enhanced post-meal glucose management, demonstrating its promise as a clinical decision-support tool in standard diabetic care.

In order to improve real-time diabetes care, Zecchin et al. [13] concentrated on short-term glucose forecasting using neural networks. It has been demonstrated that accurate glucose prediction improves everyday diabetes treatment by helping patients and clinicians avoid hypoglycemia and hyperglycemic episodes.

In order to automate insulin delivery in diabetes treatment, Gillespie et al. [14] investigated machine learning-driven artificial pancreas devices. In addition to highlighting safety and regulatory issues for clinical use, their study showed enhanced glucose stability and decreased patient burden.

In order to tailor diabetic treatment approaches, Nguyen et al. [15] used deep learning models on electronic health information. The study demonstrated how EHR-based

forecasts might help physicians with early intervention, disease monitoring, and treatment planning, improving the standard of diabetes care.

Using clinical records, Zhang et al. [16] created machine learning models to forecast complications associated with diabetes. Early identification of high-risk patients enabled proactive healthcare strategies, supporting complication prevention in long-term diabetes management.

By enabling early screening and risk stratification at scale, Razavian et al. [17] demonstrated population-level diabetes risk prediction using large-scale EHR data, supporting public-health-oriented diabetic healthcare planning.

To ensure clinical usefulness, Marateb et al. [18] focused on interpretable machine learning models for diabetes risk prediction. The study addressed trust and responsibility in diabetes patients' healthcare decision-making by emphasizing transparency.

In their assessment of artificial intelligence applications in diabetes care, Contreras and Vehi [19] concentrated on monitoring, therapy optimization, and decision support. The review identified obstacles to clinical application while highlighting AI's potential to improve patient-centric treatment.

In order to facilitate ongoing healthcare delivery, Ting et al. [20] suggested an IoT-enabled diabetes monitoring system combined with machine learning. The device improved remote diabetes management by enabling real-time data collecting and clinical input.

In order to improve ongoing diabetic healthcare monitoring, Shao et al. [21] looked at wearable-based glucose prediction models. Their results showed how useful physiological sensor data is for anticipating glucose fluctuations and assisting with preventive care.

Mobile health apps that use machine learning for diabetes self-care were examined by Nurbekova et al. [22]. Better patient engagement, adherence, and tailored feedback in digital diabetic healthcare systems were highlighted in the study.

In order to enable early screening in diabetes management, Poplin et al. [23] used deep learning algorithms to identify diabetic retinopathy from retinal pictures. Their method supported widespread ocular screening programs by demonstrating clinical-level accuracy.

A deep learning algorithm for diabetic retinopathy identification was created by Bellema et al. [24] and is intended for use in actual healthcare settings. The study demonstrated that AI-assisted screening is feasible in diabetic care settings with limited resources.

In their evaluation of AI-based diabetic retinopathy screening tools, Ting et al. [25] showed excellent diagnosis performance. Their efforts facilitated the incorporation of automated screening into standard diabetes management procedures.

Using clinical data, Yoon et al. [26] suggested machine learning methods to forecast diabetic neuropathy. It has been demonstrated that early risk prediction reduces long-term handicap in diabetes patients and supports preventive healthcare interventions.

Saito et al. [27] concentrated on applying machine learning methods to forecast the course of diabetic nephropathy. Their results demonstrated enhanced renal risk assessment, which supports early clinical intervention in the treatment of diabetes.

Explainable artificial intelligence is a crucial prerequisite for healthcare applications, including diabetes control, according to Holzinger et al. [28]. The findings emphasized that patient safety and professional trust depend on interpretability.

With regard to diabetic management, Guidotti et al. [29] examined interpretable machine learning techniques in medical diagnostics. The study emphasized techniques for clinical decision support that strike a compromise between precision and openness.

Interpretable models can reach excellent predictive accuracy in healthcare risk prediction, as shown by Caruana et al. [30]. Their results supported the use of transparent models in clinical diabetic decision-making.

Federated learning frameworks were investigated by Rieke et al. [31] in order to facilitate collaborative diabetes healthcare analytics without jeopardizing patient privacy. Secure multi-institutional learning for diabetes prediction was facilitated by the method.

Federated machine learning was used by Xu et al. [32] to forecast diabetes in remote healthcare systems. Their findings addressed ethical issues in diabetes research by demonstrating efficient efficiency while preserving data confidentiality.

Privacy-preserving machine learning methods that can be applied to diabetes healthcare data were examined by Kaissis et al. [33]. The study emphasized that secure model training is crucial for clinical deployment that complies with regulations.

An IoT-based personalized diabetes prediction system was presented by Alhussein [34] to facilitate ongoing medical monitoring. Early detection and tailored intervention were enhanced by the use of real-time data.

Kavakiotis et al. [35] reviewed machine learning techniques applied in diabetes healthcare research. The study summarized predictive, diagnostic, and monitoring applications while identifying gaps in clinical translation.

In order to forecast diabetes in healthcare settings, Shamshirband et al. [36] looked at ensemble machine learning techniques. Reliable clinical decision assistance was supported by the study's increased accuracy and robustness.

Deep learning applications in diabetes care, such as diagnosis, monitoring, and treatment optimization, were examined by Taheri et al. [37]. The study highlighted how deep neural

networks are increasingly helping to improve patient outcomes.

An unsupervised learning system for electronic health data was presented by Choi et al. [38], which enhanced the prediction of diseases, including diabetes. The strategy promoted comprehensive patient representation for individualized medical care.

Wu et al. [39] examined machine learning applications in the treatment of type 2 diabetes with an emphasis on management, prediction, and categorization. The paper outlined developments as well as ongoing difficulties in applying AI models to therapeutic settings.

3. Comparative Analysis and Final Conclusion

Significant advancements have been made in a number of areas of diabetes management, including risk prediction, glucose forecasting, complication identification, and medication optimization, according to a thorough analysis of current machine learning-based diabetic healthcare systems. Using structured clinical data, traditional supervised learning models like Random Forests, Decision Trees, and Support Vector Machines have shown dependable performance in predicting diabetes risk. Nevertheless, these methods are mostly restricted to static analysis and frequently rely significantly on manually created characteristics, which limits their capacity to adjust to changing patient circumstances.

In terms of prediction accuracy and robustness, ensemble and boosting-based techniques- such as Gradient Boosting, XGBoost, and LightGBM- have continuously surpassed single classifiers, especially for large-scale datasets. These models are better at figuring out who is at risk and diagnosing diabetes early, but they mostly make predictions about whole populations and don't offer much personalization for ongoing diabetes management. For clinical decision-making, their interpretability is still an issue.

When it comes to predicting temporal glucose trends using CGM data and wearable sensors, deep learning techniques- particularly LSTM networks, Temporal Convolutional Networks, and Autoencoders- have demonstrated greater performance. These models provide a significant leap in continuous diabetes monitoring by enabling real-time glucose prediction and early detection of unfavorable glycemic episodes. However, the therapeutic scalability of deep learning models is limited since they frequently function as black boxes, lack transparency, and require huge, high-quality datasets.

By identifying unique phenotypes and subgroups with differing risks and patterns of disease progression, unsupervised clustering techniques have provided important insights into diabetes heterogeneity. These techniques are mainly descriptive and infrequently incorporated into real-time decision-support or treatment systems, despite their support for precision medicine. Similar to this, methods based on reinforcement learning have shown promise in adaptive therapy and individualized insulin dosing, but they encounter real-world issues with clinical trust, computational complexity, and safety validation.

Wearable, mobile, and IoT-enabled health systems have improved patient participation and real-time monitoring, allowing for ongoing data collecting outside of clinical settings. Nevertheless, the majority of current systems operate as separate parts and do not seamlessly integrate with clinical procedures, predictive analytics, or individualized decision support. Furthermore, many systems still fail to adequately handle privacy, interoperability, and data governance issues.

Overall, the comparative research shows that while current systems are excellent at handling particular diabetes management activities, they are unable to provide a cohesive, end-to-end, individualized healthcare solution. Integrating prediction, monitoring, phenotypic identification, and treatment optimization into a unified, comprehensible, and privacy-preserving framework that can function well in actual healthcare settings is a glaring research gap.




Figure 2: Comparative Effectiveness of Machine Learning Techniques for Identifying Diabetes Patients

4. Direction of Future Work

The next stage of development will concentrate on creating an integrated personalized diabetic healthcare framework that incorporates several machine learning paradigms in response to the shortcomings found in current systems. The suggested system will include deep learning for continuous glucose forecasting, unsupervised clustering for patient phenotypic identification, supervised learning for risk and complication prediction, and reinforcement learning for adaptive therapy recommendations.

To guarantee openness and clinical interpretability of forecasts and recommendations, a particular focus will be on implementing explainable artificial intelligence algorithms. Federated and privacy-preserving learning procedures, which allow for cooperative model training across institutions without disclosing sensitive patient data, will be investigated in order to address privacy and data-sharing concerns. To facilitate comprehensive patient modeling, multimodal data integration from wearables, continuous glucose monitoring, electronic health records, and lifestyle inputs will also be given top priority.

To guarantee openness and clinical interpretability of forecasts and recommendations, a particular focus will be on implementing explainable artificial intelligence algorithms. Federated and privacy-preserving learning procedures, which

allow for cooperative model training across institutions without disclosing sensitive patient data, will be investigated in order to address privacy and data-sharing concerns. To facilitate comprehensive patient modeling, multimodal data integration from wearables, continuous glucose monitoring, electronic health records, and lifestyle inputs will also be given top priority.

References

- [1] H. Faris et al., "An intelligent system for diabetes prediction using machine learning algorithms," *Information Sciences*, 2019.
- [2] Y. Han et al., "Machine learning models for diabetes risk prediction: A systematic review," *Diabetes Research and Clinical Practice*, 2020.
- [3] D. Sisodia and D. S. Sisodia, "Prediction of diabetes using classification algorithms," *Procedia Computer Science*, 2018.
- [4] M. M. Rahman and M. Rashid, "Comparative analysis of machine learning algorithms for diabetes prediction," *Journal of Big Data*, 2021.
- [5] K. Li et al., "Blood glucose prediction using deep neural networks: A systematic review," *Sensors*, 2020.
- [6] I. Fox et al., "Deep learning for predicting glucose levels from CGM data," *Nature Medicine*, 2021.
- [7] H. Peng et al., "Reinforcement learning for personalized insulin therapy," *IEEE Journal of Biomedical and Health Informatics*, 2018.
- [8] E. Ahlqvist et al., "Novel subgroups of adult-onset diabetes identified using clustering analysis," *The Lancet Diabetes & Endocrinology*, 2018.
- [9] M. S. Udler, "Type 2 diabetes genetic subtypes based on clustering," *Nature Medicine*, 2018.
- [10] J. M. Dennis et al., "Precision medicine in diabetes: Classification based on cluster analysis," *Diabetes Care*, 2019.
- [11] C. D. Man et al., "The UVA/Padova type 1 diabetes simulator," *Journal of Diabetes Science and Technology*, 2014.
- [12] J. Xie et al., "Personalized insulin bolus advisor using machine learning," *Diabetes Technology & Therapeutics*, 2021.
- [13] C. Zecchin et al., "Neural network approaches for short-term glucose forecasting," *IEEE Transactions on Biomedical Engineering*, 2017.
- [14] D. T. Gillespie et al., "Artificial pancreas systems using ML for personalized insulin control," *Nature Biomedical Engineering*, 2020.
- [15] P. Nguyen et al., "Deep learning applied to EHR data for personalized diabetes care," *NPJ Digital Medicine*, 2020.
- [16] J. Zhang et al., "Risk prediction of diabetes complications using ML on EHRs," *Scientific Reports*, 2021.
- [17] N. Razavian et al., "Population-level prediction of diabetes using EHR and ML models," *JAMIA*, 2015.
- [18] H. R. Marateb et al., "Personalized diabetes risk models using interpretable ML," *Computers in Biology and Medicine*, 2021.
- [19] I. Contreras and J. Vehi, "Artificial intelligence for diabetes management and decision support: A review," *Journal of Diabetes Science and Technology*, 2018.
- [20] J. Ting et al., "IoT-enabled ML monitoring system for diabetes patients," *IEEE Access*, 2020.
- [21] Y. Shao et al., "Wearable-based prediction of glucose variations using ML," *Sensors*, 2021.
- [22] Z. Nurbekova et al., "Mobile health applications for diabetes self-management using ML techniques," *Healthcare*, 2021.
- [23] R. Poplin et al., "Predicting diabetic retinopathy using deep learning," *Nature Biomedical Engineering*, 2018.
- [24] V. Bellefleur et al., "Deep learning for diabetic retinopathy detection," *Ophthalmology*, 2019.
- [25] D. Ting et al., "Screening for diabetic retinopathy using AI," *JAMA*, 2017.
- [26] K. H. Yoon et al., "Machine learning prediction of diabetic neuropathy," *PLOS ONE*, 2020.
- [27] H. Saito et al., "Prediction of diabetic nephropathy using ML models," *Diabetes Care*, 2021.
- [28] A. Holzinger et al., "Explainable AI in healthcare," *Wiley Interdisciplinary Reviews: Data Mining*, 2019.
- [29] R. Guidotti et al., "Interpretable machine learning in medical diagnosis," *ACM Computing Surveys*, 2018.
- [30] R. Caruana et al., "Interpretable ML models for healthcare risk prediction," *ICML*, 2015.
- [31] N. Rieke et al., "Federated learning in healthcare," *Nature Communications*, 2020.
- [32] J. Xu et al., "Federated ML for diabetes prediction," *IEEE Access*, 2021.
- [33] G. Kaissis et al., "Privacy-preserving machine learning in medical data," *Nature Machine Intelligence*, 2020.
- [34] M. Alhussein, "Personalized diabetes prediction using IoT and ML," *Future Generation Computer Systems*, 2020.
- [35] I. Kavakiotis et al., "Machine learning and data mining applied in diabetes research," *Computational and Structural Biotechnology Journal*, 2017.
- [36] S. Shamshirband et al., "Ensemble ML techniques for diabetes prediction," *Journal of Medical Systems*, 2020.
- [37] S. Taheri et al., "Deep learning applications in diabetes," *Diabetes & Metabolic Syndrome*, 2021.
- [38] E. Choi et al., "Deep patient: Unsupervised representation learning for EHRs," *Scientific Reports*, 2016.
- [39] Y. Wu et al., "Machine learning in type 2 diabetes classification, prediction and management," *Journal of Diabetes Research*, 2020.